Role of sodium-glucose co-transporter-2 inhibitors in the management of heart failure in patients with diabetes mellitus

• 作者: Konstantinos Tziomalos Stelina Alkagiet
• 来源期刊: 世界糖尿病杂志:英文版(电子版)
• 学科: 地球科学
• 关键词: Heart failure Type 2 diabetes mellitus Sodium-glucose co-transporter-2 inhibitors Canagliflozin DAPAGLIFLOZIN Empagliflozin
• 年，卷（期）: 2020,（5）
• 页码范围: 150-154
• 页数: 5页
• 分类号: X70

摘要

Heart failure(HF)is a major complication of diabetes mellitus(DM).Patients with DM have considerably higher risk for HF than non-diabetic subjects and HF is also more severe in the former.Given the rising prevalence of DM,the management of HF in diabetic patients has become the focus of increased attention.In this context,the findings of several randomized,placebo-controlled trials that evaluated the effects of sodium-glucose co-transporter-2 inhibitors on the risk of hospitalization for HF in patients with type 2 DM represent a paradigm shift in the management of HF.These agents consistently reduced the risk of hospitalization for HF both in patients with and in those without HF.These benefits appear to be partly independent from glucose-lowering and have also been reported in patients without DM.However,there are more limited data regarding the benefit of sodium-glucose co-transporter-2 inhibitors in patients with HF and preserved left ventricular ejection fraction,which is the commonest type of HF in diabetic patients.